Robert Davis, Merck CEO
June 22, 2022 10:27 AM EDT
Deals
Bioregnum

In lieu of hard M&A news, one group of an­a­lysts crunch­es the num­bers around a $40B Seagen buy

Some of the an­a­lysts at SVB Se­cu­ri­ties have been play­ing with the num­bers that might set the stage for Mer­ck $MRK — or some oth­er Big …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study

Ex­clu­sive: Aven­zo picks up an­oth­er ADC, this time with mul­ti-part­nered Du­al­i­ty­Bio

Ken Song's Can­did li­cens­es a T cell en­gager from WuXi Bio

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

A service from the Financial Times